STXS

$1.89

Pre-MarketAs of Mar 17, 8:00 PM UTC

Stereotaxis, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.89
Potential Upside
5%
Whystock Fair Value$1.98
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$180.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-143.56%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.05

Recent News

GuruFocus.com
Mar 10, 2026

Stereotaxis Inc (STXS) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Advances ...

Stereotaxis Inc (STXS) reports a 36% revenue increase in Q4 2025, driven by system sales and strategic product launches, despite facing manufacturing and transition challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 9, 2026

Stereotaxis Q4 Earnings Call Highlights

Stereotaxis (NYSEAMERICAN:STXS) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight a year of regulatory milestones, a shifting business model toward higher recurring revenue, and near-term execution priorities centered on manufacturing ramp-ups and early comme

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 9, 2026

Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

Stereotaxis (STXS) delivered earnings and revenue surprises of +5.21% and -5.55%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 4, 2026

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates

Sight Sciences (SGHT) delivered earnings and revenue surprises of +44.83% and +0.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 3, 2026

Can Digital Subscriptions Become ISRG's New Revenue Stream in 2026?

Intuitive Surgical's My Intuitive+ may turn paid in 2026, adding a software-driven revenue layer as renewals begin and digital engagement scales.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.